yes2vaccines.org
May 12, 2026
New DNA and mRNA vaccine platforms are advancing, but a broadly available hantavirus vaccine is still not imminent.
The recent Andes virus outbreak has renewed attention on a major gap in infectious-disease preparedness: there is still no FDA-licensed vaccine for hantavirus pulmonary syndrome, including disease caused by Andes virus. Some inactivated hantavirus vaccines targeting hemorrhagic fever with renal syndrome are licensed in China and South Korea, but there is no widely approved vaccine for Andes virus or Sin Nombre virus, the main causes of severe hantavirus pulmonary syndrome in the Americas.
One of the most important recent advances is a first-in-human Andes virus DNA vaccine trial. In a Phase 1 randomized, double-blind, dose-escalation study, researchers evaluated an Andes virus DNA vaccine delivered by needle-free jet injection in 48 healthy adults. The vaccine encoded the Andes virus envelope glycoproteins Gn and Gc, which are major targets of neutralizing antibodies. The study found that the candidate was generally safe and induced a durable immune response, with several cohorts reaching at least 80% seropositivity by day 197, sustained through day 337.
Research has also advanced for other hantavirus species. A 2024 npj Vaccines Phase 1 study tested Hantaan and Puumala virus DNA vaccines delivered by needle-free injection. The individual vaccines were safe and well tolerated, and neutralizing antibody responses were observed in 100% of subjects receiving the Hantaan vaccine alone and 100% of those receiving the Puumala vaccine alone, although the combined vaccine showed weaker dual seroconversion.
A newer direction is mRNA-LNP vaccine design. Moderna has confirmed early-stage hantavirus vaccine research, including collaboration with the Vaccine Innovation Center at Korea University College of Medicine. Reporting indicates the work began before the current cruise-ship outbreak and remains preclinical, meaning it is not close to public availability.
Another major scientific advance came in 2026 from a Nature Communications study using a prefusion-stabilized Hantaan virus glycoprotein immunogen. In mouse studies, both DNA and mRNA-LNP versions generated strong neutralizing antibody responses, activated germinal-center immunity, and protected animals against high-dose Hantaan virus challenge. The mRNA-LNP version also worked as a potent booster after prior inactivated vaccine priming.
These studies show that hantavirus vaccine science is moving forward, especially through nucleic-acid vaccine platforms such as DNA and mRNA. However, several challenges remain: hantaviruses are genetically diverse, protection may need to cover multiple regional strains, human correlates of protection are not fully established, and the market for a rare disease is small—making sustained public and nonprofit investment especially important.
Yes2Vaccines take-home message:The current outbreak does not mean a hantavirus vaccine is ready today, but it does show why vaccine platforms matter. DNA and mRNA technologies can accelerate preparedness for rare, deadly, and neglected pathogens before they become global emergencies.